 Adamis Pharmaceuticals is moving TEMPOL forward against COVID-19. The FDA recently announced that they submitted a Fast Track application for TEMPOL. TEMPOL has the potential to both prevent disease progression and reduce replication. I match TEMPOL up against contemporary COVID-19 products. 